TY - JOUR
T1 - Measuring Drug Metabolism Kinetics and Drug-Drug Interactions Using Self-Assembled Monolayers for Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
AU - Anderson, Lyndsey L.
AU - Berns, Eric J.
AU - Bugga, Pradeep
AU - George, Alfred L.
AU - Mrksich, Milan
N1 - Funding Information:
This work was funded by the Defense Threat Reduction Agency (Grant HDTRA1-15-1-0052 to M.M.) and a Dixon Translational Research Grants Initiative. L.L.A is the recipient of a postdoctoral fellowship grant from the PhRMA Foundation.
Publisher Copyright:
© 2016 American Chemical Society.
PY - 2016/9/6
Y1 - 2016/9/6
N2 - The competition of two drugs for the same metabolizing enzyme is a common mechanism for drug-drug interactions that can lead to altered kinetics in drug metabolism and altered elimination rates in vivo. With the prevalence of multidrug therapy, there is great potential for serious drug-drug interactions and adverse drug reactions. In an effort to prevent adverse drug reactions, the FDA mandates the evaluation of the potential for metabolic inhibition by every new chemical entity. Conventional methods for assaying drug metabolism (e.g., those based on HPLC) have been established for measuring drug-drug interactions; however, they are low-throughput. Here we describe an approach to measure the catalytic activity of CYP2C9 using the high-throughput technique self-assembled monolayers for matrix-assisted laser desorption-ionization (SAMDI) mass spectrometry. We measured the kinetics of CYP450 metabolism of the substrate, screened a set of drugs for inhibition of CYP2C9 and determined the Ki values for inhibitors. The throughput of this platform may enable drug metabolism and drug-drug interactions to be interrogated at a scale that cannot be achieved with current methods.
AB - The competition of two drugs for the same metabolizing enzyme is a common mechanism for drug-drug interactions that can lead to altered kinetics in drug metabolism and altered elimination rates in vivo. With the prevalence of multidrug therapy, there is great potential for serious drug-drug interactions and adverse drug reactions. In an effort to prevent adverse drug reactions, the FDA mandates the evaluation of the potential for metabolic inhibition by every new chemical entity. Conventional methods for assaying drug metabolism (e.g., those based on HPLC) have been established for measuring drug-drug interactions; however, they are low-throughput. Here we describe an approach to measure the catalytic activity of CYP2C9 using the high-throughput technique self-assembled monolayers for matrix-assisted laser desorption-ionization (SAMDI) mass spectrometry. We measured the kinetics of CYP450 metabolism of the substrate, screened a set of drugs for inhibition of CYP2C9 and determined the Ki values for inhibitors. The throughput of this platform may enable drug metabolism and drug-drug interactions to be interrogated at a scale that cannot be achieved with current methods.
UR - http://www.scopus.com/inward/record.url?scp=84985995256&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84985995256&partnerID=8YFLogxK
U2 - 10.1021/acs.analchem.6b01750
DO - 10.1021/acs.analchem.6b01750
M3 - Article
C2 - 27467208
AN - SCOPUS:84985995256
SN - 0003-2700
VL - 88
SP - 8604
EP - 8609
JO - Analytical Chemistry
JF - Analytical Chemistry
IS - 17
ER -